Haemonetics Corporation $HAE Stake Lessened by Citigroup Inc.

Citigroup Inc. decreased its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 89.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 429,041 shares of the medical instruments supplier’s stock after selling 3,769,576 shares during the quarter. Citigroup Inc. owned 0.89% of Haemonetics worth $20,911,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Parkside Financial Bank & Trust grew its stake in Haemonetics by 11.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock valued at $109,000 after acquiring an additional 152 shares in the last quarter. Retirement Systems of Alabama grew its position in Haemonetics by 0.4% during the second quarter. Retirement Systems of Alabama now owns 61,401 shares of the medical instruments supplier’s stock valued at $4,581,000 after purchasing an additional 256 shares in the last quarter. Teacher Retirement System of Texas grew its position in Haemonetics by 3.9% during the second quarter. Teacher Retirement System of Texas now owns 7,636 shares of the medical instruments supplier’s stock valued at $570,000 after purchasing an additional 285 shares in the last quarter. Quantinno Capital Management LP increased its stake in Haemonetics by 9.0% in the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 289 shares during the period. Finally, CWC Advisors LLC. lifted its position in Haemonetics by 7.8% in the 3rd quarter. CWC Advisors LLC. now owns 4,551 shares of the medical instruments supplier’s stock worth $222,000 after buying an additional 328 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Key Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Zacks nudged FY2026 EPS slightly higher to $4.95 (from $4.93), and raised its Q2 2027 estimate to $1.37 (from $1.35) — small upside near‑term beats that may cushion downside from other cuts. Zacks estimate updates (Feb 24)
• Neutral Sentiment: Zacks published a comprehensive set of updated quarterly and fiscal estimates (Q4 2026 – Q3 2028 and FY2026–FY2028), providing a refreshed model investors can use to re‑rate the stock. Zacks estimate updates (Feb 24)
• Negative Sentiment: Material downward revisions to the medium/longer term: Zacks cut FY2028 EPS to $5.73 from $5.90 and trimmed FY2027 to $5.34 from $5.37 — signaling lower expected growth beyond FY2026. Zacks estimate updates (Feb 24)
• Negative Sentiment: Zacks lowered multiple quarterly forecasts across 2026–2028 (examples: Q1 2028 to $1.35 from $1.39; Q1 2027 to $1.19 from $1.20; Q3 2028 to $1.51 from $1.53; Q2 2028 to $1.46 from $1.50; Q4 2027 and Q4 2026 also trimmed). These repeated downgrades put near‑term EPS risk on the table. Zacks estimate updates (Feb 24–25)

Haemonetics Stock Down 0.2%

Shares of HAE stock opened at $62.21 on Friday. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. The firm has a market cap of $2.89 billion, a PE ratio of 17.14, a price-to-earnings-growth ratio of 1.30 and a beta of 0.28. The stock has a 50 day moving average of $70.47 and a 200-day moving average of $63.96.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The business had revenue of $338.97 million for the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the previous year, the firm posted $1.19 earnings per share. Haemonetics’s revenue was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. On average, equities analysts predict that Haemonetics Corporation will post 4.55 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Barrington Research set a $94.00 price target on shares of Haemonetics in a report on Friday, February 6th. Citigroup lowered their target price on Haemonetics from $88.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research note on Saturday, January 10th. Mizuho reduced their price target on Haemonetics from $90.00 to $80.00 and set an “outperform” rating for the company in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. increased their price objective on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a report on Friday, December 12th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $84.44.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.